Modulation of Calcium Oxalate Dihydrate Growth by Selective Crystal-face Binding of Phosphorylated Osteopontin and Polyaspartate Peptide Showing Occlusion by Sectoral (compositional) Zoning

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2009 Jul 8

PMID 19581305

Citations 29

Authors

Yung-Ching Chien

David L Masica

Jeffrey J Gray

Sarah Nguyen

Hojatollah Vali

Marc D McKee

Affiliations

Soon will be listed here.

Abstract

Calcium oxalate dihydrate (COD) mineral and the urinary protein osteopontin/uropontin (OPN) are commonly found in kidney stones. To investigate the effects of OPN on COD growth, COD crystals were grown with phosphorylated OPN or a polyaspartic acid-rich peptide of OPN (DDLDDDDD, poly-Asp(86-93)). Crystals grown with OPN showed increased dimensions of the {110} prismatic faces attributable to selective inhibition at this crystallographic face. At high concentrations of OPN, elongated crystals with dominant {110} faces were produced, often with intergrown, interpenetrating twin crystals. Poly-Asp(86-93) dose-dependently elongated crystal morphology along the {110} faces in a manner similar to OPN. In crystal growth studies using fluorescently tagged poly-Asp(86-93) followed by imaging of crystal interiors using confocal microscopy, sectoral (compositional) zoning in COD was observed resulting from selective binding and incorporation (occlusion) of peptide exclusively into {110} crystal sectors. Computational modeling of poly-Asp(86-93) adsorption to COD {110} and {101} surfaces also suggests increased stabilization of the COD {110} surface and negligible change to the natively stable {101} surface. Ultrastructural, colloidal-gold immunolocalization of OPN by transmission electron microscopy in human stones confirmed an intracrystalline distribution of OPN. In summary, OPN and its poly-Asp(86-93) sequence similarly affect COD mineral growth; the {110} crystallographic faces become enhanced and dominant attributable to {110} face inhibition by the protein/peptide, and peptides can incorporate into the mineral phase. We, thus, conclude that the poly-Asp(86-93) domain is central to the OPN ability to interact with the {110} faces of COD, where it binds to inhibit crystal growth with subsequent intracrystalline incorporation (occlusion).

Citing Articles

Understanding the structural biology of osteomalacia through multiscale 3D X-ray and electron tomographic imaging: a review of X-linked hypophosphatemia, the mouse model, and imaging methods.

Buss D, Deering J, Reznikov N, McKee M JBMR Plus. 2025; 9(2):ziae176.

PMID: 39896117 PMC: 11783288. DOI: 10.1093/jbmrpl/ziae176.

Annexin-derived self-assembling peptide nanostructures for alleviation of calcium oxalate -induced renal injury.

Saha S, Mishra A Urolithiasis. 2024; 53(1):5.

PMID: 39666033 DOI: 10.1007/s00240-024-01678-w.

Ab Initio Molecular Dynamics Simulations of Phosphocholine Interactions with a Calcium Oxalate Dihydrate (110) Surface.

Morris R, Chappell H, Scott A, Borissova A, Smith J Cryst Growth Des. 2024; 24(19):8063-8075.

PMID: 39372599 PMC: 11450748. DOI: 10.1021/acs.cgd.4c01032.

The impact of crystal phase transition on the hardness and structure of kidney stones.

Michibata U, Maruyama M, Tanaka Y, Yoshimura M, Yoshikawa H, Takano K Urolithiasis. 2024; 52(1):57.

PMID: 38563829 PMC: 10987347. DOI: 10.1007/s00240-024-01556-5.

Increased abundance of bacteria of the family Muribaculaceae achieved by fecal microbiome transplantation correlates with the inhibition of kidney calcium oxalate stone deposition in experimental rats.

Wang Y, Sun J, Xie S, Zhou Y, Wang T, Liu Z Front Cell Infect Microbiol. 2023; 13:1145196.

PMID: 37313343 PMC: 10258309. DOI: 10.3389/fcimb.2023.1145196.

References

Pampena D, Robertson K, Litvinova O, Lajoie G, Goldberg H, Hunter G . Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J. 2003; 378(Pt 3):1083-7. PMC: 1224036. DOI: 10.1042/BJ20031150. View

Sodek J, Ganss B, McKee M . Osteopontin. Crit Rev Oral Biol Med. 2000; 11(3):279-303. DOI: 10.1177/10454411000110030101. View

Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F . Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001; 60(5):1645-57. DOI: 10.1046/j.1523-1755.2001.00032.x. View

Kleinman J, Wesson J, Hughes J . Osteopontin and calcium stone formation. Nephron Physiol. 2004; 98(2):p43-7. DOI: 10.1159/000080263. View

Pedraza C, Chien Y, McKee M . Calcium oxalate crystals in fetal bovine serum: implications for cell culture, phagocytosis and biomineralization studies in vitro. J Cell Biochem. 2007; 103(5):1379-93. DOI: 10.1002/jcb.21515. View

Gericke A, Qin C, Spevak L, Fujimoto Y, Butler W, Sorensen E . Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int. 2005; 77(1):45-54. PMC: 1451414. DOI: 10.1007/s00223-004-1288-1. View

Addadi L, Weiner S . Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci U S A. 1985; 82(12):4110-4. PMC: 397944. DOI: 10.1073/pnas.82.12.4110. View

Makrodimitris K, Masica D, Kim E, Gray J . Structure prediction of protein-solid surface interactions reveals a molecular recognition motif of statherin for hydroxyapatite. J Am Chem Soc. 2007; 129(44):13713-22. DOI: 10.1021/ja074602v. View

Ryall R, Hibberd C, Marshall V . A method for studying inhibitory activity in whole urine. Urol Res. 1985; 13(6):285-9. DOI: 10.1007/BF00262658. View

10.

Hoyer J, Asplin J, Otvos L . Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int. 2001; 60(1):77-82. DOI: 10.1046/j.1523-1755.2001.00772.x. View

11.

Khan S . Animal models of kidney stone formation: an analysis. World J Urol. 1997; 15(4):236-43. DOI: 10.1007/BF01367661. View

12.

Masica D, Gray J . Solution- and adsorbed-state structural ensembles predicted for the statherin-hydroxyapatite system. Biophys J. 2009; 96(8):3082-91. PMC: 2718269. DOI: 10.1016/j.bpj.2009.01.033. View

13.

Sheng X, Jung T, Wesson J, Ward M . Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci U S A. 2004; 102(2):267-72. PMC: 544292. DOI: 10.1073/pnas.0406835101. View

14.

Dyer R, Nordin B . Urinary crystals and their relation to stone formation. Nature. 1967; 215(5102):751-2. DOI: 10.1038/215751a0. View

15.

Mandel N . Crystal-membrane interaction in kidney stone disease. J Am Soc Nephrol. 1994; 5(5 Suppl 1):S37-45. DOI: 10.1681/ASN.V55s37. View

16.

Fisher L, Torchia D, Fohr B, Young M, Fedarko N . Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001; 280(2):460-5. DOI: 10.1006/bbrc.2000.4146. View

17.

Chutipongtanate S, Nakagawa Y, Sritippayawan S, Pittayamateekul J, Parichatikanond P, Westley B . Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor. J Clin Invest. 2005; 115(12):3613-22. PMC: 1288833. DOI: 10.1172/JCI25342. View

18.

Wesson J, Worcester E . Formation of hydrated calcium oxalates in the presence of poly-L-aspartic acid. Scanning Microsc. 1996; 10(2):415-23; 423-4. View

19.

Wesson J, Johnson R, Mazzali M, Beshensky A, Stietz S, Giachelli C . Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol. 2002; 14(1):139-47. DOI: 10.1097/01.asn.0000040593.93815.9d. View

20.

Lieske J, Deganello S . Nucleation, adhesion, and internalization of calcium-containing urinary crystals by renal cells. J Am Soc Nephrol. 1999; 10 Suppl 14:S422-9. View